Antibodies and conjugates that target misfolded prion protein
US9296819B2 · kind B2 · utility
1Cited by
0References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 11, 2013 |
| Grant date | Mar 29, 2016 |
| Priority date | — |
| Expiry date | Jun 11, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2828
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human prion protein, PrP, selectively presents the epitope MDEYSNQNN (SEQ ID No. 14) when PrP misfolds. The misfolded form of human PrP is associated with various disease states. The present invention provides an antibody useful to detect and treat such diseases, including cancer such as ovarian cancer and lymphomas, and transmissible spongiform encephalopathies such as CJD. Also provided is an immunoconjugate in which the antibody is conjugated with urease as cytotoxin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.